Fig. 4: mRBC-OVA-4-1BBL-IL-12 and mRBC-4-1BBL-IL-12 delays EG7.OVA tumor growth in mice without OT-1 transfer. | Nature Communications

Fig. 4: mRBC-OVA-4-1BBL-IL-12 and mRBC-4-1BBL-IL-12 delays EG7.OVA tumor growth in mice without OT-1 transfer.

From: Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic

Fig. 4

a C57BL/6 mice were inoculated subcutaneously with 2 × 106 EG7.OVA cells. Following that, 1 × 109 mRBC-CTRL, or a dose titration of mRBC-4-1BBL-IL-12 or mRBC-OVA-4-1BBL-IL-12 (1 × 109, 3 × 108) was administered (n = 8) on days 1, 4, 8, 11, 15, and 18. b Tumor growth curve after treatments. c OVA tetramer+ CD8+ T cells in 50 μL blood. Two-way ANOVA compared to mRBC-CTRL; 1 × 109 mRBC-4-1BBL-IL-12: day 18 P = 0.0057, day 21 P = 0.014; 3 × 108 mRBC-OVA-4-1BBL-IL-12: day 11 P = 0.0087, day 14 P = 0.023; 1 × 109 mRBC-OVA-4-1BBL-IL-12: days 7 and 11 P < 0.0001, day 14 P = 0.006, and day 18 P = 0.017. Data are depicted as mean ± s.d. and are representative of two independent experiments. Source data are provided as a Source Data file.

Back to article page